( DURHAM N.C.--(BUSINESS WIRE)--May 4 2...)Argos Therapeutics Presents Immunosuppression Data for Soluble CD83,at the American Society of Transplantation Congress 2007,Health

DURHAM, N.C.--(BUSINESS WIRE)--May 4, 2007 - Argos Therapeutics today announced the presentation of data on the immunosuppressive properties of soluble CD83 at the 7th Joint American Transplant meeting to be held in San Francisco, May 5-9. The presentations will be made in collaboration with scientists at the University of Western Ontario.

"These data suggest that soluble CD83 is able to extend graft survival in transplantation, and that it can also act synergistically with other immunosuppressive agents," commented Dr. Stephen Brand, Director of Biotherapeutics at Argos Therapeutics. "sCD83 appears to be able to maintain antigen presenting cells in an immature state, and these immunologically tolerant cells favor regulatory T-cell generation because they are less effective in activating naive T and B cells."

"This emerging activity profile for sCD83, as well as its ability to suppress antibody production without systemic suppression, may provide advantages over currently available B-cell targeting therapies," said Dr. Charles Nicolette, Chief Scientific Officer and Vice President of Research and Development of Argos. "The extended graft survival that we have observed thus far indicates that sCD83 could potentially provide enhanced organ function, without immune rejection, and may serve to reduce the toxic profile associated with many commonly used immunotherapeutic agents. These data support Argos' plans to conduct additional studies with CD83 in transplantation and autoimmune models, which will provide important information as we develop a clinical strategy for this candidate."

Data will be discussed in the following presentations:

-- Abstract # 1697: "Soluble CD83 in combination with Rapamycin and anti-CD45RB monoclonal antibody induces long-term graft survival in a mouse cardiac transplantation model"

-- Abstract #116: "Soluble CD83 can inhibit B-cell activation and differentiati
'"/>

Page: 1 2
Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
5. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
9. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
10. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
11. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care